Draft whitepaper
Beyond Injectable Metabolic Therapeutics
A category thesis on oral metabolic peptides, gut-lumen biology, and the next therapeutic architecture after the first GLP-1 wave.
What is inside
The paper separates mechanism crowding from architecture crowding, arguing that GLP-1 success validates metabolic biology without exhausting the design space.
It frames DPP-4 and GLP-1 biology as early modules inside a broader oral metabolic peptide systems thesis, with gut-proximal activity, modular design, and route constraints treated as core discovery questions.
Who should read it
- Partners exploring metabolic peptide opportunities.
- Investors evaluating post-GLP-1 architecture theses.
- Teams considering oral-route or gut-proximal discovery programs.
Request access
Ask for the whitepaper
Share a few details and Metastate will review the request before sending the draft manually. The PDF is not available as an automatic public download.
Form submissions are processed through Formspree. See the privacy policy for data handling details.